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Abstract 
Objective: Whether intracerebral haemorrhage (ICH) associated with non-vitamin K 
antagonist oral anticoagulants (NOAC-ICH) has a better outcome compared to ICH 
associated with vitamin-K antagonists (VKA-ICH) is uncertain.  
Methods: We performed a systematic review and individual patient data meta-analysis of 
cohort studies comparing clinical and radiological outcomes between NOAC-ICH and VKA-
ICH patients. The primary outcome measure was 30-day all-cause mortality. All outcomes 
were assessed in multivariable regression analyses adjusted for age, sex, ICH location and 
intraventricular haemorrhage extension. 
Results: We included 7 eligible studies comprising 219 NOAC-ICH and 831 VKA-ICH 
patients (mean age:77 years,52.5% females). The 30-day mortality was similar between 
NOAC-ICH and VKA-ICH (24.3% vs. 26.5%; HR=0.94, 95%CI: 0.67 to 1.31). However, in 
multivariable analyses adjusting for potential confounders, NOAC-ICH was associated with: 
lower admission National Institutes of Health Stroke Scale (NIHSS) score (linear regression 
coefficient=-2.83, 95%CI:-5.28 to -0.38); lower likelihood of severe stroke (NIHSS>10 
points) on admission (OR=0.50, 95%CI: 0.30 to 0.84); and smaller baseline haematoma 
volume (linear regression coefficient=-0.24,95%CI:-0.47 to -0.16). The two groups did not 
differ in the likelihood of: baseline haematoma volume less than 30cm
3
 (OR=1.14, 95%CI: 
0.81 to 1.62); haematoma expansion (OR=0.97, 95%CI: 0.63 to 1.48); in-hospital mortality 
(OR=0.73,95%CI: 0.49 to 1.11); functional status at discharge (common OR=0.78, 95%CI: 
0.57 to 1.07);  or functional status at three months (common OR=1.03, 95%CI: 0.75 to 1.43).  
Interpretation: Although functional outcome at discharge, one month or three months were 
comparable after NOAC-ICH and VKA-ICH, patients with NOAC-ICH had smaller baseline 
haematoma volumes and less severe acute stroke syndromes. 
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Text 
Introduction 
Intracerebral haemorrhage (ICH) is the most feared complication of oral 
anticoagulation with mortality approaching 50%.
1
 Despite advances in primary prevention 
and especially the treatment of hypertension, the global incidence of ICH has remained 
stable,
2
 in part due to the increase of anticoagulant-related ICH in the elderly.
3
 
 Use of oral anticoagulation with vitamin K antagonists (VKA) is known to double the 
ICH risk even under optimal treatment conditions [international normalized ratio (INR) 
between 2 and 3]; the annual risk of ICH is estimated to range from 0.3% to 0.6% per year.
4.5
 
Apart from the increased incidence, VKA associated ICH (VKA-ICH) is associated with 
larger haematoma volumes, increased case fatality and poor functional outcome.
6,7
 Non-
vitamin K antagonist oral anticoagulants (NOAC) have similar efficacy in ischaemic stroke 
prevention in patients with non-valvular atrial fibrillation (NVAF), with half the incidence of 
ICH compared to warfarin.
8 
Even though the pharmacodynamics, short half-life and 
discriminate anticoagulant action of NOACs have been associated with the lower risk of 
incident ICH, findings are conflicting regarding the outcome of patients with NOAC 
associated ICH (NOAC-ICH) compared to VKA-ICH.
9,10
 
We therefore performed a systematic review and individual patient data meta-analysis 
(IPDM), including data from available cohort studies comparing clinical and radiological 
outcomes between NOAC-ICH and VKA-ICH patients. 
 
Methods 
Literature search and trial identification 
This meta-analysis is presented according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses for Individual Patient Data (PRISMA-IPD) 
guidelines
11
 and was written according to the Meta-analysis of Observational Studies in 
Epidemiology (MOOSE) proposal.
12 
We followed a pre-specified study protocol that has been 
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9 
published in the International Register PROSPERO (International Prospective Register of 
Ongoing Systematic Reviews).
13  
Eligible study protocols reporting clinical and radiological characteristics of NOAC-
ICH in comparison to VKA-ICH were identified by searching MEDLINE and SCOPUS. The 
combination of search strings that was used in all database searches included the terms: 
“intracerebral haemorrhage”, “intracranial haemorrhage”, “intracranial bleeding”, “cerebral 
haemorrhage”, “cerebral haematoma”, “vitamin K antagonists” (including also the names of 
all pharmaceutical substances), “novel oral anticoagulants”, “direct oral anticoagulants”, 
“non-vitamin K antagonist oral anticoagulants” (including also the names of all 
pharmaceutical substances). No language or other restrictions were imposed. Last literature 
search was conducted on August 25th, 2017. Reference lists of all articles that met our 
inclusion criteria and of relevant review articles were examined to identify studies that may 
have been missed by the initial database search. Literature searches were performed by two 
independent teams of reviewers (GT & AHK, DW & DJW), while emerging disagreements 
were resolved with consensus. 
Data transfer and verification 
Anonymised data were transferred from participating centres to the Coordinating and 
Data Management Centre (National Hospital for Neurology and Neurosurgery, Queen Square 
University College Hospitals, NHS Foundation Trust). The data obtained from each 
participating study were checked with respect to range, internal consistency, consistency with 
published reports and missing items.
14
 Inconsistencies or missing data were discussed with 
the individual principal investigators and emerging problems were resolved with consensus. 
Finally, data supplied were either recoded or transformed to reflect common definitions and 
common units of measurement across the generated individual patient database, while 
computer-generated detailed summary tabulations based on the converted data were returned 
to each collaborator for review and verification. 
Inclusion criteria, exclusion criteria and outcomes of interest 
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To be eligible for inclusion in the IPDM individual studies, registries or databases 
(reported variously as prospective or retrospective observational cohort studies or trials) were 
asked to include data available for compulsory baseline characteristics of interest [age, sex, 
oral anticoagulant agent, ICH location (lobar vs non-lobar), intraventricular haemorrhage 
(IVH) extension in baseline neuroimaging] and survival data (number of days from index 
event to death). The list of non-compulsory variables that were requested is available in the 
Supplementary Table 1.  
Haematoma volume was calculated with the same method for NOAC-ICH and VKA-
ICH using either the ABC/2 method or planimetric measurement with adjustments made for 
multilobar haemorrhage and scans with non-uniform slice thickness.
15
 Haematoma expansion 
at follow-up neuroimaging was defined as an absolute increase of more than 12.5 cm
3
 or a 
relative increase of more than 33% in haematoma volume at the follow-up scan compared to 
the admission neuroimaging.
16
 In patients with sufficient data we additionally calculated the 
corresponding CHA2DS2-VASc scores,
17
 in case not provided in the original databases. 
In the present IPDM we included patients older than 18 years of age with diagnosis of 
acute primary ICH, who were confirmed to be receiving VKA (with INR>1.5 on admission)
18
 
or NOAC (definite evidence of intake within 24h before the ICH onset). We excluded 
patients with ICH secondary to trauma (i.e. major head trauma thought to be sufficient to 
have caused the ICH in the previous 24h), vascular malformation, tumour, cavernoma, 
aneurysm, or haemorrhagic transformation of ischaemic stroke. We additionally excluded 
patients with primary subarachnoid haemorrhage (with or without an ICH component), 
isolated intraventricular bleeding, and VKA-ICH patients with INR≤1.5 on admission.13 
The primary outcome was 30-day all-cause mortality between NOAC-ICH and VKA-
ICH. Secondary outcomes were admission stroke severity [assessed with the National 
Institutes of Health Stroke Scale score (NIHSS)]; severe stroke (NIHSS >10) on admission,
19
 
level of consciousness (quantified by Glasgow Coma Scale score) on admission, haematoma 
volume on admission; small haematoma volume (<30cm
3
) rates on admission,
20
 haematoma 
expansion rate on follow-up neuroimaging, in-hospital mortality, functional status at 
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11 
discharge and at three months, quantified by the distribution of modified Rankin Scale (mRS) 
scores.  
Quality assessment in included studies 
We used the Newcastle-Ottawa Scale to assess the quality of each observational study 
that met our inclusion criteria.
21
 According to this scale, a maximum of one star can be 
awarded for each item within the selection and exposure/outcome categories and a maximum 
of two stars for the comparability category; studies can earn a maximum of 9 star-points. 
Quality control and bias identification were performed by two independent reviewers (DW & 
GA) and all disagreements were resolved with consensus.
21
 
Statistical analysis 
We summarised normally distributed continuous variables as means with 
corresponding standard deviations (SDs), while non-normally distributed variables were 
reported as medians with their corresponding interquartile ranges (IQRs). All categorical 
variables were presented as absolute numbers with corresponding percentages.  
Univariate Kaplan Meier survival probabilities were estimated for each anticoagulant 
group; the log rank test was used to compare groups. For the primary pre-specified outcome 
analysis, we fitted a Cox proportional hazards model with a frailty term for study. In this 
observational study, the exposure (NOAC vs VKA) precedes acute ICH and thus the exposure 
itself might affect some of the markers of ICH severity (ICH volume and GCS). For 
multivariable models of the outcome variables (mortality, functional outcomes) we therefore 
only included covariates which should not be affected by anticoagulant choice (age, sex, ICH 
location and IVH extension); we added  a shared frailty term to allow for possible site related 
factors (e.g. general ICH management, resources, ethnicity). The assumption of proportional 
hazards was assessed using Schoenfeld residuals.  
For the secondary outcomes of interest we performed mixed effects multivariable 
logistic or ordinal regression analyses, as indicated. Anticoagulant (NOAC vs. VKA), age, 
sex, IVH extension and ICH location were treated as fixed effects and registry as a random 
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12 
effect in each analysis exploring clinical severity or functional outcome/mortality, whilst 
anticoagulant (NOAC vs. VKA), age, sex and ICH location were treated as fixed effects and 
registry as a random effect in the analysis exploring ICH volume and ICH expansion. 
Associations in all logistic and ordinal regression analyses are presented using odds ratios 
(OR) and common ORs (cOR) respectively with their corresponding 95% confidence 
intervals (CI).
13
 In the final multivariable analyses statistical significance was achieved if 
two-sided p<0.05, calculated using the likelihood ratio test. In multivariable models, we 
excluded patients with missing data from the analysis; we did not impute missing data. 
Where applicable, the adjusted individual study results were displayed using a forest 
plot and a two stage meta-analysis was performed to calculate I
2
, a measure of heterogeneity 
across studies, and τ2, a measure of variance of the true effect sizes.22 The pooled estimate 
was suppressed in these plots since their sole purpose here is to display the results from each 
individual study. 
Finally we performed pre-specified subgroup analyses on the primary outcome 
according to the NOAC drug used (apixaban, dabigatran, rivaroxaban), reporting the relevant 
p-value for interaction for each one.  
 
Results 
Study selection and study characteristics 
Systematic search of MEDLINE and SCOPUS databases yielded 600 and 684 results 
respectively. After removing duplicates, the titles and abstracts from the remaining 974 
studies were screened and 12 potentially eligible studies for the meta-analysis were retained. 
After retrieving the full-text version of the aforementioned 12 studies, 3 studies were 
excluded because they included patients with traumatic brain injury
23-25
 and 1 study due to the 
lack of VKA-ICH comparator group (Supplementary Table 2).
26
 In the final presentation of 
the literature search results, there was no conflict or disagreement between the reviewers and 
the corresponding authors from the 8 studies that met the protocol’s inclusion criteria were 
contacted by e-mail. Individual patient data were obtained from all study protocols, except for 
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13 
one,
27
 and the 7 eligible studies were finally included in the qualitative and quantitative 
synthesis (Figure 1).
28-34  
Prior to applying our own inclusion and exclusion criteria, we received 100% of 
expected patient numbers from each study (Supplementary Table 3). No important issues with 
IPD integrity were identified after checks according to PRISMA checklist recommendations. 
Quality assessment of included studies highlighted one study
32
 that reported enrolment of 
some VKA patients before the start of enrolment of their first NOAC patient (Supplementary 
Table 4). 
After excluding 74 patients on a VKA with an inital INR value ≤1.5 we were left 
with a total of 1050 patients (219 on NOACs and 831 on a VKA) from 7 individual studies. 
Baseline characteristics and outcomes of the total 1050 eligible ICH patients (NOAC-ICH: 
219, VKA-ICH: 831, mean age: 77 years, 52.5% women) are summarized in Supplementary 
Table 5. The use of any reversal strategy was approximately three times more common 
(p<0.001) in VKA-ICH patients (n=621, 89%) compared to NOAC-ICH patients (n=58, 
31%). More specifically, use of vitamin K was reported in 25% and 75% of NOAC-ICH and 
VKA-ICH patients, respectively. Protein complex concentrate was used in 21% and 79% of 
NOAC-ICH and VKA-ICH patients, while fresh frozen plasma was used in 22% and 78% of 
NOAC-ICH and VKA-ICH patients, respectively. Use of a specific reversal agent 
(idarucizumab) was reported in only one patient with NOAC-ICH.
33
 
 
Primary analysis 
Two studies had follow up times which were too short to allow inclusion into our 
primary outcome of 30 day mortality. Therefore our primary analysis was comprised 909 
patients from five studies. In survival analysis, adjusting for age, sex, ICH location and IVH 
extension as well as clustering by centre, NOAC-ICH and VKA-ICH patients did not differ in 
the risk of 30-day mortality (24.3% vs. 26.5%; adjusted HR= 0.94, 95%CI: 0.67 to 1.31, 
p=0.702; Figure 2 & Table 1). The proportional hazard assumption was not violated (global 
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14 
test p=0.247). Unadjusted Kaplan-Meier plots for each included study on the primary 
outcome of 30-day mortality are available in the Figure 3.  
In a post-hoc sensitivity analysis, including the 74 VKA-ICH patients with INR 
values ≤1.5 and the patients from the 2 centres with short follow-up times (after imputation of 
missing baseline values) we documented similar results for the risk of 30-day mortality 
between NOAC- and VKA-ICH patients (HR=0.90, 95% CI 0.66 to 1.21, p=0.476; Table 1). 
 
Secondary outcomes 
Results of adjusted analyses on secondary outcomes of interest are presented in Table 
1 and in the Supplemental Table 6 - Supplemental Table 15. An overview of unadjusted 
analyses on the primary and secondary outcomes of interest is provided in the Supplemental 
Table 16 & Figure 4. Four studies comprising of 398 patients had information available on 
NIHSS. NOAC-ICH was associated with lower admission NIHSS scores (adjusted linear 
regression coefficient= -2.83, 95%CI: -5.28 to -0.38) and a lower likelihood of severe stroke 
(NIHSS>10 points) on admission (adjusted OR= 0.50, 95%CI: 0.30 to 0.84).  
Four studies comprising 845 patients had data available on GCS. In adjusted analysis 
the two groups did not differ in GCS-score on hospital admission (adjusted linear regression 
coefficient= -0.01, 95%CI: -0.57 to 0.55).  
Seven studies comprising 1006 patients had data available on ICH volume. NOAC-
ICH was associated with smaller baseline haematoma volumes on admission (adjusted linear 
regression coefficient= -0.24, 95%CI: -0.47 to -0.16). However, the odds of admission 
haematoma volume being less than 30cm
3
 did not differ between the groups (adjusted OR= 
1.14, 95%CI: 0.81 to 1.62)  
Seven studies comprising of 617 patients had data available on ICH expansion on 
follow up neuroimaging, which did not differ between the two groups (adjusted OR= 0.97, 
95%CI: 0.63 to 1.48) 
Seven studies comprising of 902 patients had data on in-hospital mortality and mRS 
at discharge. However, one of the studies did not collect data on IVH extension, thus could 
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15 
not be included in multivariable analysis. In adjusted analysis comprising of 824 patients 
from 6 studies no significant differences between the two groups were found regarding in-
hospital mortality (adjusted OR= 0.73, 95%CI: 0.49 to 1.11) and functional status at hospital 
discharge (adjusted cOR per 1-point increase in mRS-score= 0.78, 95%CI: 0.57 to 1.07). 
Three studies comprising of 748 patients had data available on 90 day mRS which 
again shows no statistical difference between the groups (adjusted cOR= 1.03, 95%CI: 0.75 to 
1.43). 
Analysis of individual NOAC drug type (Table 2) revealed no significant differences 
in their 30-day mortality risk compared with VKA (apixaban: adjusted HR=0.56, 95%CI: 
0.20 to 1.51, dabigatran: adjusted HR=0.69, 95%CI: 0.34 to 1.40, rivaroxaban adjusted 
HR=1.11, 95%CI: 0.78 to 1.68; overall p=0.267; Figure 5). 
 
Discussion 
Our IPDM showed comparable 30-day mortality rates after NOAC-ICH and VKA-
ICH, with no statistically significant differences in risk for different NOAC agents. However, 
NOAC-ICH was independently associated with less severe acute ICH as measured by 
baseline haematoma volume and stroke severity (NIHSS) on admission. VKA-ICH and 
NOAC-ICH had similar functional outcome at discharge and at three-month follow-up.  
 Our findings highlighting similar outcomes in NOAC-ICH and VKA-ICH patients 
differ from those reported from a recent retrospective analysis from the Get With The 
Guidelines–Stroke (GWTG-Stroke) registry, including 141,311 total ICH patients admitted in 
1662 US hospitals, suggesting that NOAC-ICH patients have lower risk of in-hospital 
mortality and functional disability at discharge compared to VKA-ICH patients.
35 
This 
disparity could be attributed to the more stringent definition of oral anticoagulant related ICH 
in patients from our cohort compared to that used in the cohort from the GWTG-Stroke 
registry (any use of oral anticoagulant within 7 days prior to hospital arrival), and the lack of 
adjustment for baseline stroke severity in the multivariable models of in-hospital mortality 
and functional outcome in both GWTG-Stroke registry and our protocol.
35
 Our study provides 
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an invaluable insight in the anticoagulant-related ICH neuroimaging outcomes, which are 
known to be significant predictors of clinical outcomes but in turn are less affected by 
demographic characteristics compared to clinical outcomes. Taking into account that 
demographic characteristics have been inadequately assessed in our study protocol and in the 
study by Inohara et al,
35
 the importance of findings on neuroimaging outcomes is further 
highlighted. We also consider that the results from the current IPDM, incorporating data from 
international multicenter cohorts, are likely to be more easily generalizable to every clinical 
setting. Finally, it should be noted that findings from a very recent meta-analysis of available 
randomized clinical trials on the use of NOACs for the prevention of thromboembolism in 
patients with NVAF, suggesting similar case fatality rates in NOAC-related and VKA-related 
ICH,
36
 corroborate further our results on the similar 30-day mortality risk between NOAC- 
and VKA-related ICH patients and contradict further the finding of lower in-hospital 
mortality risk for NOAC-ICH patients reported in the study by Inohara et al.
35
 
Our results are also in accordance with a previously published systematic review and 
pairwise meta-analysis of aggregate level data from 12 observational studies (393 NOAC-
ICH and 3482 VKA-ICH), suggesting no significant differences in haematoma expansion, 
mortality and functional outcome between NOAC-ICH and VKA-ICH patients.
36
 A non-
significant association for lower baseline ICH volume in NOAC-ICH compared to VKA-ICH 
was also reported in this meta-analysis (standardized mean difference: -0.24; 95% CI -0.52 to 
0.04, p=0.093), while the association of NOAC-related ICH with 30-day mortality was not 
evaluated in this meta-analysis.
37 
 
 The finding of lower baseline haematoma volumes in NOAC-ICH compared to 
VKA-ICH could be attributed to the more favourable pharmacological properties of NOACs, 
including shorter plasma half-life and selective inhibition of the extrinsic coagulation 
pathway, compared to VKAs.
38
 The one-to-one direct stoichiometric inhibition of thrombin or 
factor Xa by NOACs favours the physiological cerebrovascular haemostatic response after an 
ICH, in contrast to the impaired haemostasis due to thrombin substrates deficiency induced by 
VKAs.
39
 However, although haematoma volume on admission is associated with stroke 
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severity,
40
 and long-term outcome after an ICH,
41 
we detected no significant differences 
between NOAC-ICH and VKA-ICH patients in 30-day mortality risk, the rate of haematoma 
expansion, in-hospital mortality, or functional outcome at discharge and 3-month follow-up. 
Since the trajectory of recovery of ICH might be slower than that after ischaemic stroke,
42
 it is 
possible that with longer follow-up the apparent benefits of NOACs on acute ICH volume and 
stroke severity might translate into better functional outcome. Longer term studies of outcome 
after VKA- and NOAC-ICH will be needed to investigate this possibility.  
Our study has strengths. We included a large sample of individual participant data 
allowing us to perform adjusted analyses for both clinical and radiological outcomes between 
NOAC-ICH and VKA-ICH. We included high quality observational studies, using pre-
specified inclusion criteria at both study and individual patient level. However, there are also 
several limitations that should be taken into consideration. First, individual participant data 
from one study including 27 participants was not available,
27
 but we consider the potential 
impact of this to be negligible. Second, although we collected detailed baseline data, we were 
not able to assess and further adjust the potential impact of some clinical (e.g. the degree of 
blood pressure reduction),
43
 laboratory (e.g. cholesterol levels on admission)
44
 and 
neuroimaging (e.g. presence of cerebral microbleeds or cortical superficial siderosis)
45-48 
parameters on the outcomes of interest. It should also be noted that there was no central 
adjudication in image analysis for both baseline and follow-up neuroimaging scans. 
Moreover, since patients in the two groups were not randomized to NOAC or VKA 
administration, imbalances in both baseline characteristics and other potential confounders, 
including onset-to-neuroimaging time,
49
 could be present. Despite adjustment for baseline 
factors, there is also a risk of residual confounding by indication, which is not completely 
addressed in current IPDM or in the previous report from the GWTG-Stroke registry.
35
 
Moreover, it should also be noted that we were unable to assess for the temporal and 
geographical differences in ICH care or practice patterns, including the choice and 
administration timing of reversal agents, which are known to influence ICH outcomes. Due to 
complexity of reasons for clinician selection of an anticoagulant regimen for particular 
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patients and the presence of significant disparities in ICH management we consider that only 
randomised controlled trial data will be able to firmly account for these potential biases. 
The availability of reversal strategies for oral anticoagulants and the timing of their 
administration after ICH onset could also account for potential difference in outcomes 
between NOAC- and VKA-ICH patients in the present IPDM. The use of any reversal 
strategy was approximately three times more common in VKA-ICH than in NOAC-ICH 
cases. Given that NOAC-specific reversal agents may be associated with a lower case fatality 
rate in NOAC-related ICH,
36
 the more widespread future use of these agents might result in a 
substantial decrease of NOAC-ICH mortality. 
Due to the lack of significant differences in clinical outcomes between NOAC-ICH 
and VKA-ICH, despite the disparities in neuroimaging findings, we performed a post-hoc 
power calculation to investigate for the possibility of a ceiling effect and underpowering; this 
indicated that our IPDM had 80% power to detect a 10% absolute difference (and a 
corresponding HR of 0.56) for the primary outcome of interest (30-day mortality) between 
NOAC- and VKA-ICH patients. Thus, our IPDM was not powered to detect smaller 
differences in the 1-month mortality rates between NOAC-ICH and VKA-ICH patients. We 
note that the adjusted absolute risk difference in the in-hospital mortality that was detected in 
the GWTG-Stroke registry was 6%.
35
 The missing functional evaluations in 20% and 30% of 
our study population at discharge and at three months may have diluted the potential 
beneficial effect of NOACs on functional outcomes in ICH patients, but these were secondary 
outcomes. Since pre-morbid mRS scores were not available in the included study protocols, 
the lack of significant differences on clinical outcomes could also be attributed to the inability 
for adjustment for the presence of disability prior to index event. Finally, as in the primary 
analysis, we consider the subgroup analysis according to NOAC regimen underpowered and 
the risk of residual confounding in the NOAC-ICH subgroup possible.  
In conclusion, our IPDM provides preliminary evidence that although 30-day clinical 
outcomes appear to be comparable between NOAC-ICH and VKA-ICH patients, NOAC-ICH 
may be related to lower baseline haematoma volumes and lower admission stroke severity 
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scores. This observation requires independent confirmation in larger prospective cohort 
studies adjusting for all potential confounders, including neuroimaging parameters and pre-
ICH functional status. Longer term follow-up studies should determine whether outcomes 
beyond 30 days differ between VKA- and NOAC-ICH.  
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Table 1. Overview of primary and secondary adjusted analyses 
 
Outcome Number 
of studies  
Number of 
patients 
Effect size for NOAC (95% 
confidence interval) 
p-value 
Primary outcome     
30-day mortality 5 909 HR= 0.94  
(0.67 to 1.31) 
0.702 
30-day mortality (sensitivity 
analysis)* 
7 1098 HR=0.90 
(0.66 to 1.21) 
0.476 
Secondary outcomes     
Admission NIHSS 4 398 LRC= -2.83  
(-5.28 to -0.38) 
0.024 
Admission NIHSS more 
than 10 
4 398 OR= 0.50 
(0.30 to 0.84)  
0.009 
Baseline GCS 4 845 LRC= -0.01  
(-0.57 to 0.55)  
0.979 
Baseline ICH volume** 7 1006 LRC= -0.24  
(-0.47 to -0.16)  
0.036 
Baseline haematoma 
volume less than 30 cm3** 
7 1006 OR= 1.14 
(0.81 to 1.62)  
0.447 
Haematoma expansion** 7 617 OR= 0.97 
(0.63 to 1.48)  
0.883 
In-hospital mortality 6 824 OR= 0.73 
(0.49 to 1.11)  
0.140 
mRS at hospital discharge 6 824 cOR= 0.78 
(0.57 to 1.07) 
0.127 
mRS at 90 days 3 748 cOR= 1.03 
(0.75 to 1.43)  
0.842 
 
 
*including the 74 VKA-ICH patients with INR values INR <1.5 and after imputation of the 
patients from 2 centres with short follow-up times 
** Adjusted for age, sex and ICH location. The remainder adjusted for age, sex IVH 
extension and ICH location. 
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HR: hazard ratio, OR: odds ratio, NIHSS: National Institutes of Health Stroke Scale, GCS: 
Glasgow Coma Scale, ICH: intracerebral haemorrhage, mRS: modified Rankin Scale; cOR: 
common odds ratio; LRC: linear regression coefficient, IVH: intraventricular haemorrhage 
extension 
 
 
 
Table 2. Adjusted subgroup analysis on the primary outcome of 30-day mortality according 
to the type of non-vitamin K oral anticoagulant based upon 5 studies and 909 patients 
 HR 95% CI p value 
VKA  Baseline   
Rivaroxaban  1.11 0.78 to 1.68 0.494 
Dabigatran  0.69 0.34 to 1.40 0.300 
Apixaban 0.56 0.20 to 1.51 0.249 
Age (per year increase) 1.02 1.01 to 1.04 0.006 
Sex (female/ male) 1.13 0.87 to 1.46 0.370 
IVH (yes/no) 3.16 2.39 to 4.16 <0.001 
ICH location (lobar/ non-
lobar) 
1.19 0.91 to 1.55 0.211 
 
 
HR: hazard ratio, 95%CI: 95% confidence interval, VKA: vitamin k oral anticoagulant, IVH: 
intraventricular haemorrhage extension, ICH: intracerebral haemorrhage 
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FIGURES 
 
Figure 1. Flow chart presenting the selection of eligible studies. 
Figure 2. Adjusted for each included study cox regression analyses on the primary outcome 
of 30-day mortality between patients receiving pretreatment with non-Vitamin K antagonist 
oral anticoagulants and patient receiving treatment with Vitamin K antagonist oral 
anticoagulants 
Figure 3. Unadjusted Kaplan-Meier plots for each included study on the primary outcome of 
30-day mortality. 
Figure 4. Unadjusted Kaplan Meier curves on the probability of 30-day survival between 
patients with intracerebral haemorrhage related to non-vitamin k antagonist oral 
anticoagulants and patients with intracerebral haemorrhage related to vitamin k antagonist 
oral anticoagulants. 
Figure 5. Subgroup analysis on the risk of 30-day mortality in patients with intracerebral 
haemorrhage related to the use of different non-vitamin k antagonist oral anticoagulants. 
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